Letzo

Letrozole, the active ingredient in Letzo, is an aromatase inhibitor presented as an oral formulation for oral use. It is used in the endocrine therapy of estrogen receptor‑positive breast cancer in postmenopausal women, helping to reduce estrogen production that can stimulate tumor growth. The drug works by reversibly binding to the aromatase enzyme, thereby decreasing the conversion of androgens to estrogens. Clinical studies have demonstrated its efficacy in both early‑stage and advanced disease settings, making it a cornerstone of hormonal management for this patient population.

GNH USA supplies Letzo as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Letrozole is indicated for hormone‑dependent breast cancer and works within the estrogen signaling pathway. - Adjuvant treatment of early‑stage estrogen receptor‑positive breast cancer in postmenopausal women: reduces risk of disease recurrence after surgery. - Metastatic hormone receptor‑positive breast cancer in postmenopausal women: slows tumor progression and extends survival. - Neoadjuvant therapy for estrogen receptor‑positive breast cancer in postmenopausal women: decreases tumor size before surgery.

Letrozole may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Joint and muscle pain: aches in joints or muscles. - Fatigue: persistent tiredness. - Nausea: mild to moderate upset stomach. - Headache: pressure or throbbing pain. - Weight gain: increase in body weight.

Serious or Rare Side Effects: - Severe bone loss: increased risk of osteoporosis and fractures. - Cardiovascular events: blood clots or stroke. - Liver toxicity: elevated liver enzymes or hepatitis. - Allergic reactions: rash, itching, swelling, or anaphylaxis.

Before initiating Letzo, clinicians should consider several safety measures and monitoring requirements. - Assess bone health: baseline DEXA scan recommended. - Monitor liver function: periodic liver enzyme tests. - Evaluate cardiovascular risk: check blood pressure and lipid profile. - Avoid use in premenopausal women: drug is ineffective without ovarian suppression. - Inform patients about potential hot flashes and joint pain. - Store at ambient temperature: keep below 25°C, protect from moisture and light.

Letrozole can interact with other medicines, altering its effectiveness or increasing toxicity.

Major Interactions (Avoid): - Concurrent use with estrogen‑containing hormone therapy: negates aromatase inhibition. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce plasma levels. - Tamoxifen: antagonistic effects on estrogen pathways.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin): may increase bleeding risk. - Selective serotonin reuptake inhibitors (SSRIs): possible additive effect on bone density loss. - Cholesterol‑lowering agents (statins): monitor liver function.